Epidemiological studies indicate that sudden cardiac death is the cause of 20–159 deaths per 100,000 residents per year in Europe and 84–200 deaths/100,000 residents/year in the United States. According to the current recommendations of cardiological societies, patients with a history of myocardial infarction and reduced ejection fraction (EF < 35 %) should be protected by cardioverter–defibrillator implantation. Impaired EF has been shown to be a marker of increased cardiovascular mortality and sudden cardiac death [1, 2], but it has relatively low sensitivity for detecting arrhythmia and sudden cardiac death risk [3].

The diagnosis of mechanical dysynchrony induced by the presence of infarction scar and/or conduction abnormalities in patients with an EF of < 35 % may be associated with a greater propensity for inducing serious ventricular arrhythmia [ventricular tachycardia (VT), ventricular fibrillation (VF)] and sudden cardiac death [1, 2], but it has relatively low sensitivity for detecting arrhythmia and sudden cardiac death risk [3].

The assessment of regional myocardial function using tissue Doppler echocardiography (TDE) allows for noninvasive analysis of the regional mechanical dysfunction (LV mechanical dispersion). Therefore, the aim of this study was to evaluate mechanical dispersion as an echocardiographic predictor of VT/VF.

Patients and methods

The study group consisted of 47 consecutive patients with cardiac resynchronization therapy defibrillator (CRT-D) devices implanted in the Department of Cardiology, Congenital Heart Diseases and Electrotherapy, of the Silesian Center for Heart Diseases in Zabrze between 2008 and 2009. All patients who were included in the study met the criteria for CRT-D implantation, had an EF of < 35 %, and were followed up for more than 3 years. The study population was divided into two groups: Group 1 (n = 29) comprised patients who had recorded episodes of arrhythmic events; group 2 (n = 18) comprised patients who did not have any registered arrhythmic events within 4 years after implantation.

Arrhythmic events were defined as ventricular arrhythmias that required appropriate antitachycardia pacing or shock released by an implantable cardioverter–defibrillator (ICD) and included both VF and sustained VT (sVT). All data on arrhythmic events were reviewed retrospectively by a physician experienced in clinical pacing.

Echocardiography

An echocardiographic study including standard measurement and TDE was completed for each patient before device implantation using the Vivid 5 System (GE-Vingmed, GE Healthcare). Digital echocardiographic recordings were analyzed retrospectively using ECHOPAC 9.0 software (GE Healthcare). A quantitative assessment of left ventricular (LV) regional deformation was based on the color tissue velocity recordings. In our study, global LV function parameters were calculated: LV end-diastolic diameter (LVEDD), LV end-systolic diameter (LVESD), interventricular septum (IVS) thickness, LV posterior wall (LVPW) thickness, end-systolic volume (ESV), end-diastolic volume (EDV), as well as regional LV function parameters—strain parameters (time to peak strain and post-systolic strain) and velocity parameters (time to onset velocity, time to peak velocity, and time to end of systole) (Fig. 1). LV EF was assessed according to Simpson’s biplane method. Myocardial strain was calculated based on the color tissue velocity data recorded in two-chamber and four-chamber apical view. Subsequently, longitudinal strain was quantified for each myocardial segment [4]. LV
mechanical dispersion was defined as the standard deviation of the time measured from the beginning of the QRS complex to peak longitudinal segmental strain.

**Statistical analysis**

Continuous parameters are expressed as means with standard deviations, categorical variables are presented as numbers and percentages. Comparative analysis between groups was performed using Student’s t test for continuous variables and the chi-square test, as appropriate, for dichotomous parameters. All p values less than 0.05 were considered significant. The dispersion value with optimal sensitivity and specificity was identified with the use of receiver-operating characteristics.

**Results**

Post-CRT-D implantation arrhythmic events were recorded in 29 patients (group 1), whereas 18 patients did not experience arrhythmia (group 2). Four patients of group 1 and two of group 2 received a CRT-D for secondary prevention (13.79 vs. 11.11 %, p = 0.789). The clinical characteristics of the patients are presented in Table 1. There were no significant differences between groups according to age, sex, and body mass index. No significant differences between groups were observed for ischemic diseases, chronic heart failure, arterial hypertension, hyperlipidemia, and atrial fibrillation. Patients suffering from cardiomyopathy predominated in group 1 (79.31 % in group 1 vs. 44.44 % in group 2, p = 0.014). There was no significant difference in QRS duration, mean blood pressure, hematocrit, INR, and potassium level between the two groups. No significant differences between groups were observed regarding the intake of beta-adrenergic blocking agents and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

The average time to event after implantation was 345 ± 317 days. Echocardiographic findings are presented in Table 2. There were significant differences between groups 1 and 2 with respect to the timing of mechanical dispersion: (99.14 ± 33.60 vs. 72.98 ± 19.70 ms, p = 0.002). However, there were no significant differences between groups in terms of other echocardiographic parameters.

**Patients with ischemic heart failure**

Among the analyzed patients, those with ischemic etiology (patients after myocardial infarction and patients suffering from coronary artery disease or ischemic cardiomyopathy) were selected and divided into two groups: group ISCH 1 comprising patients with VT/VF (n=15) during follow-up and group ISCH 2 comprising patients without VT/VF events during follow-up (n=14). The results and echocardiographic characteristics for patients with heart failure of ischemic etiology are presented in Table 3. The average time to event post-device implantation in this
LV mechanical dispersion as a predictor of ventricular arrhythmia in patients with advanced systolic heart failure. A pilot study

Abstract

Background. Myocardial mechanical dys-synchrony induced by the presence of postin-farction scar and/or conduction abnormalities in patients with a left ventricular ejection fraction (LVEF) < 35% may be associated with a greater propensity toward inducing serious ventricular arrhythmia (ventricular tachycardia (VT), ventricular fibrillation (VF)) and sudden cardiac death. The assessment of regional myocardial function using tissue Doppler echocardiography (TDE) allows for noninvasive analysis of regional mechanical dysfunction (LV mechanical dispersion).

Aim. The aim of this study was to evaluate the TDE-based mechanical dispersion as a potential echocardiographic predictor of VT/VF.

Methods. The study group consisted of 47 consecutive ambulatory patients with implanted cardiac resynchronization therapy-defibrillator (CRT-D) devices who were divid- ed into two groups: Group 1 (n = 29) comprised patients with recorded episodes of VT/VF, in whom baseline TDE data were avail- able, and group 2 (n = 18) comprised patients without registered VT/VF in the device mem- ory within 4 years after implantation. LV me- chanical dispersion was defined as the standard deviation of the time measured from the beginning of the QRS complex to the peak longitudinal strain in apical four-cham- ber and two-chamber views. A retrospective quantitative assessment of LV regional deform- ation was based on the color tissue veloc- ity recordings.

Results. The average time to event after im- plantation was 345 days. Patients with elec- trical events demonstrated greater mecha- nical dispersion: 99.14 ± 33.60 vs. 72.98 ± 19.70, p = 0.002.

Conclusion. During the 4-year follow-up, pa- tients with documented VT/VF were charac- terized by significantly higher LV mechanical dispersion as compared with patients with- out electrical events. Measurement of LV me- chanical dispersion might be helpful in deter- mining the risk of sudden cardiac death.

Keywords
Dilated cardiomyopathy · Sudden cardiac death · Implantable cardioverter-defibrillator · Mechanical dyssynchrony · Ultrasound strain

LV mechanische Dispersion als Prädiktor ventrikulärer Arrhythmie bei Patienten mit fortgeschrittener systolischer Herzinsuffizienz. Eine Pilotstudie

Zusammenfassung

Hintergrund. Eine myokardiale mecha- nische Dyssynchrone, die durch eine Narbe nach Infarkt und/oder Erregungsleitungs- störungen bei Patienten mit linksventrikulärer Ejektionsfraktion (LVEF) < 35 % induziert wird, kann mit einem höheren Risiko der Induktion schwerer ventrikulärer Arrhythmien (ventrikuläre Tachykardie, VT; Kammerflimmern) und plötzlichem Herztod einherge- hen. Die Untersuchung der regionalen Myo- kardfunktion mit der Gewebsdopplerecho- kardiographie (TDE) ermöglicht die nichtin-vasive Erkennung einer regionalen mecha- nischen Dysfunktion (mechanische LV-Dis- persion).

Ziel. Ziel der vorliegenden Studie war es, die TDE-basierte mechanische Dispersion als potenziellen echokardiographischen Prädik- tor von VT/Kammerflimmern zu untersuchen.

Methoden. Die Studiengruppe bestand aus 47 konsekutiven ambulanten Patienten mit implantiertem CRT-D (kardialer Resynchroni- sationstherapie-Defibrillator), die in 2 Gruppen aufgeteilt wurden: Gruppe 1 (n = 29) – Patienten mit dokumentierten Episoden von VT/Kammerflimmern, bei denen Ausgangs-TDE-Daten verfügbar waren, und Gruppe 2 (n = 18) – Patienten ohne Registrierung von VT/Kammerflimmern im Gerätespeicher inner- halb von 4 Jahren nach Implantation. Die mechanische LV-Dispersion wurde definiert als Standardabweichung der gemes- senen Dauer vom Beginn des QRS-Komplexes bis zur größten longitudinalen Verformung im apikalen 4-Kammer-Blick und 2-Kammer- Blick. Eine retrospektive quantitative Beurtei- lung der regionalen LV-Verformung basier- te auf der Dokumentation der Farb-Gewebe- doppler-Geschwindigkeit.

Ergebnisse. Die durchschnittliche Dauer bis zu einem Ereignis nach Implantation betrug 345 Tage. Patienten mit elektrisch regi- trierten Ereignissen wiesen eine höhere me- chanische Dispersion auf (99,14 ± 33,60 vs. 72,98 ± 19,70; p = 0,002).

Schlussfolgerung. Während der 4-jährigen Nachbeobachtungsphase wiesen die Patien- ten mit Dokumentation von VT/Kammerflimmern eine signifikant höhere mechanische LV-Dispersion auf als die Patienten ohne elektrisch registrierte Ereignisse. Die Messung der mechanischen LV-Dispersion könnte zur Er- mittlung des Risikos für einen plötzlichen Herztod von Nutzen sein.

Schlüsselwörter
Dilatative Kardiomyopathie · Plötzlich- licher Herztod · ICD · Mechanische Dyssynchronie · Sonographische Verformung

ROC curve analysis

As presented in Fig. 2, the cutoff value for mechanical dispersion of 76 ms pro- vided 67% specificity and 83% sensitiv- ity. Measurements of mechanical disper- sion and global strain in ischemic patients add important information about the risk of sudden cardiac death apart from inform- ation provided by the EF. In patients with a preserved or slightly reduced EF, mechanical dispersion above 76 ms iden- tified ischemic patients with an increased risk of sudden cardiac death.
Discussion

The etiology of sudden cardiac death is multifactorial. Several risk factors have been identified, such as decreased LVEF, history of coronary artery disease, cigarette smoking, hypertension, obesity, male sex, heart failure, ventricular arrhythmias, increased ventricular ectopy, diminished heart rate variability, baroreflex sensitivity, and heart rate profile during exercise [5]. Randomized clinical trials indicate that 84% of sudden deaths are due to ventricular tachyarrhythmias, while bradyarrhythmias were responsible for 16% of sudden cardiac deaths. VF was the most common ventricular tachyarrhythmia, usually secondary to VT, whereas the rest of the arrhythmias were caused by torsade de pointes [6]. The best method to prevent sudden cardiac death in high-risk patients is ICD. ICD reduces mortality in patients selected for primary prevention of SCD on the basis of reduced LVEF. ICD can prevent sudden cardiac death caused by bradyarrhythmias, torsade de pointes associated with congenital long-QT syndrome (LQTS), and pause-dependent VT [7]. An impaired EF (< 35%) is the main indication for cardioverter–defibrillator implantation in patients after myocardial infarction. Hypertrophic obstructive cardiomyopathy, long QT and Brugada syndromes, and idiopathic VF are additional indications. Although LVEF is still regarded as a good predictor of ventricular arrhythmias [8, 9], it has several limitations in terms of predicting sudden cardiac death. In the Oregon Sudden Unexpected Death Study, only 30% of sudden cardiac death cases met the criteria; 65% of patients, who had LV function measured before sudden cardiac death, did not have severe LV dysfunction [10]. Other clinical studies indicated that 52% patients with sudden cardiac death had some decrease in LV systolic function, while 30% had severely decreased LV systolic function. Therefore, based on current LVEF guidelines for sudden cardiac death prevention, only 30% would have qualified as candidates for a prophylactic ICD. Patients who had sudden cardiac death and normal LVEF were more often female, younger, more likely to have a seizure disorder, and more likely to be taking antiepileptics compared with patients with decreased LVEF [11–16].

A variety of mechanisms in heart failure can lead to sudden cardiac death such as remodeling of the myocardium, altered neurohumoral signaling, slowed conduction, impaired repolarization, poor coupling of myocardium, and delayed-paced ventricular activation. These factors make the myocardium susceptible to arrhythmia triggers [17]. The presence of scar tissue in the myocardium after myocardial infarction causes electrical heterogeneity, changes in expression of ion channels, delayed electrical conduction, and dispersed recovery of excitability, and dispersed electrical repolarization. Electrophysiological testing could be an objective screening tool; however, it is invasive, expensive, and impractical. Therefore, there is a need for a sensitive tool for evaluating the risk of sudden cardiac death.

Electrical dispersion results in altered myocardial function. Regional and global myocardial function and timing can be evaluated by tissue Doppler imaging of

### Table 1 Clinical characteristics of study population

| Group 1 patients with VT/VF during follow-up (n = 29) | Group 2 patients without VT/VF during follow-up (n = 18) | p |
|------------------------------------------------------|--------------------------------------------------------|---|
| Age (years)                                          | 65.38 ± 8.81                                           | 68.50 ± 12.23 | NS |
| Sex (M = 1) n (%)                                    | 24 (82%)                                               | 12 (67%)      | NS |
| BMI                                                  | 28.02 ± 5.54                                           | 27.54 ± 4.26 | NS |
| Ischemic etiology, n (%)                             | 15 (52%)                                               | 14 (78%)      | NS |
| Arterial hypertension, n (%)                         | 11 (38%)                                               | 12 (67%)      | NS |
| Cardiomyopathy, n (%)                                | 23 (79%)                                               | 8 (44%)       | 0.014 |
| DM total, n (%)                                      | 11 (38%)                                               | 5 (28%)       | NS |
| Hyperlipidemia, n (%)                                | 7 (24%)                                                | 5 (28%)       | NS |
| Atrial fibrillation, n (%)                           | 9 (31%)                                                | 5 (28%)       | NS |
| QRS duration (ms)                                    | 161.59 ± 32.34                                         | 179.94 ± 35.42 | NS |
| Mean blood pressure (mmHg)                           | 96.94 ± 10.10                                          | 100.97 ± 12.26 | NS |
| K (mmol/l)                                           | 4.51 ± 0.49                                            | 4.44 ± 0.40   | NS |
| Pre-implantation PCI, n (%)                          | 10 (34%)                                               | 6 (33%)       | NS |
| Beta-blocker, n (%)                                  | 25 (86%)                                               | 16 (89%)      | NS |
| ACEI/ARB, n (%)                                      | 24 (83%)                                               | 15 (83%)      | NS |

**ACEI/ARB** angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, **BMI** body mass index, **DM** diabetes mellitus, **K** potassium, **NS** not significant, **PCI** percutaneous coronary intervention, **VF** ventricular fibrillation, **VT** ventricular tachycardia

### Table 2 Echocardiographic measurements in all patients

| Group 1 patients with VT/VF during follow-up (n = 29) | GR 2 patients without VT/VF during follow-up (n = 18) | p |
|------------------------------------------------------|--------------------------------------------------------|---|
| Septal flash, n (%)                                   | 14 (48%)                                               | 10 (56%) | NS |
| EF (%)                                                | 27.95 ± 10.68                                          | 28.87 ± 8.69 | NS |
| ESV (ml)                                             | 191.71 ± 90.05                                         | 179.73 ± 78.52 | NS |
| EDV (ml)                                             | 249.89 ± 108.09                                        | 215.46 ± 79.99 | NS |
| LVES dimension (mm)                                  | 67.70 ± 12.43                                          | 67.67 ± 7.74 | NS |
| LVED dimension (mm)                                  | 55.53 ± 16.38                                          | 54.67 ± 10.13 | NS |
| IVSD (mm)                                            | 11.44 ± 5.12                                           | 10.33 ± 2.73 | NS |
| IVSS (mm)                                            | 14.29 ± 5.70                                           | 14.17 ± 3.82 | NS |
| LPVWD (mm)                                           | 10.50 ± 2.39                                           | 10.20 ± 1.48 | NS |
| LPVWS (mm)                                           | 13.86 ± 4.04                                           | 13.40 ± 2.88 | NS |
| Mechanical dispersion (ms)                           | 99.14 ± 33.60                                          | 72.98 ± 19.70 | 0.002 |

**EDV** end-diastolic volume, **EF** ejection fraction, **ESV** end-systolic volume, **IVSD** interventricular septum diastolic diameter, **IVSS** interventricular septum systolic diameter, **LVES** left ventricular end systolic, **LVED** left ventricular end diastolic, **LPVWD** left ventricular posterior wall diastolic diameter, **LPVWS** left ventricular posterior wall systolic diameter, **NS** not significant
The results of our study confirmed by Norwegian researchers that sudden cardiac death was introduced for ular arrhythmia in patients with ARVC. Mechanical dispersion by myocardial strain is related to episodes of ventric- 

ular arrhythmia in patients with ARVC. More- 
als indicated mechanical dispersion to be a good tool for predicting VT/VF in pa- 

tients who are in need of better care so as to avoid sudden cardiac death.

Study limitations

It was a retrospective, pilot study covering a relatively small group of patients. Moreover, consecutive patients formed the study group, derived from a hospital database with complete digital echo and clinical data.

Conclusion

This study demonstrates that during a 4-year follow-up, patients with docu- 

mented VT/VF were characterized by sig- 

ificantly higher LV mechanical disper- 

sion compared with patients without electrical events. The measurement of LV mechanical dispersion might be helpful in determining the risk of sudden cardiac death. The determination of LV me- 

chanical dispersion in each individual pa- 

tient could be helpful in selecting pa- 

tients for ICD therapy. However, this new ultrasound-based parameter of mechanical dispersion requires further validation in a bigger cohort of patients.

Table 3  Echocardiographic measurements in patients with heart failure of ischemic etiology

|                         | ISCH 1 patients with VT/VF during follow-up (n = 15) | ISCH 2 patients without VT/ VF during follow-up (n = 14) | p   |
|-------------------------|-----------------------------------------------------|-------------------------------------------------------|-----|
| Septal flash, n (%)     | 8 (53 %)                                             | 9 (64 %)                                               | NS  |
| EF (%)                  | 29.33 ± 10.25                                        | 29.85 ± 8.91                                           | NS  |
| ESV (ml)                | 180.00 ± 79.33                                       | 173.00 ± 77.50                                         | NS  |
| EDV (ml)                | 252.67 ± 89.58                                       | 224.27 ± 81.74                                         | NS  |
| LVES dimension (mm)     | 66.50 ± 11.97                                        | 68.10 ± 7.20                                           | NS  |
| LVED dimension (mm)     | 56.22 ± 16.20                                        | 54.50 ± 9.20                                           | NS  |
| IVSS (mm)               | 11.50 ± 4.87                                        | 10.50 ± 1.29                                           | NS  |
| IVSS (mm)               | 13.00 ± 6.32                                        | 15.00 ± 1.15                                           | NS  |
| LVPWS (mm)              | 10.75 ± 3.01                                        | 10.67 ± 1.15                                           | NS  |
| LVPWD (mm)              | 13.67 ± 5.28                                        | 14.67 ± 2.08                                           | NS  |
| Mechanical dispersion (ms) | 97.80 ± 30.06                                      | 74.15 ± 15.72                                          | 0.014 |

EDV end-diastolic volume, EF ejection fraction, ESV end-systolic volume, IVSS interventricular septum diastolic diameter, IVSS interventricular septum systolic diameter, LVES left ventricular end systolic, LVED left ventricular end diastolic, LVPWS left ventricular posterior wall systolic diameter, NS not significant.

Compliance with ethical standards

Conflict of interest. G. Banasik, O. Segiet, M. Elwart, M. Szulik, R. Lenarczyk, Z. Kalarus, and T. Kukulski state that there are no conflicts of interest.

References

1. Emond M, Mock MB, Davis KB et al (1994) Long-term survival of medically treated patients in the Coronary Artery Surgery Study (CASS) Registry. Circulation 90:2645–2657
2. Quinones MA, Greenberg BH, Kopelen HA et al (2000) Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: sig- 

ificance of left ventricular hypertrophy. Studies of left ventricular dysfunction. J Am Coll Cardiol 35:1237–1244
3. Buxton AE, Lee KL, Hafley GE et al (2007) Limita- 

tions of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol 50:1150–1157
4. Pirat B, Khoury DS, Hartley CJ et al (2008) A novelty feature-tracking echocardiographic method for the quantitation of regional myocardial function: validation in an animal model of ischemia-reper- 

fusion. J Am Coll Cardiol 51:651–659
5. Cupples LA, Gagnon DR, Kannel WB (1992) Long- 

and short-term risk of sudden cardiac death: pop- 

ulation at risk. Circulation 85(Suppl 1):I11–18
6. Zipes DP (1992) Sudden cardiac death: future ap- 

proaches. Circulation 85(Suppl 1):I160–166
7. Passman R, Kadish A (2007) Sudden death pre- 

vention with implantable devices. Circulation 116:561–571
8. Bigger JT Jr, Fleiss JL, Kleiger R et al (1984) The rela- 

tionships among ventricular arrhythmias, left ventric- 

ular dysfunction, and mortality in the 2 years after myocardial infarction. Circulation 69:250–258
9. Greenberg H, McMaster P, Dwyer EM Jr (1984) Left ventricular dysfunction after acute myocardial in- 

farction: results of a prospective multicenter study. J Am Coll Cardiol 4:867–874
10. Stecker EC, Wickers C, Waltz J et al (2006) Popula- 

tion-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two year findings from the Oregon Sudden Unex- 

pected Death Study. J Am Coll Cardiol 47:1161–1166
11. Buxton AE, Lee KL, Fisher JD, Josephson ME et al (1999) Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the preven- 

tion of sudden death in patients with coronary ar- 

tery disease. N Engl J Med 341:1882–1890
HOSPITAL-Score erkennt Risiko einer Wiederaufnahme

Ein Score aus 7 Parametern, die bei der Entlassung eines Patienten einfach erhoben werden können, hat in einer internationalen Kohortenstudie die Wiederaufnahme von Patienten in den ersten 30 Tagen nach der Entlassung aus dem Krankenhaus gut vorhergesagt. Wiederaufnahmen ins Krankenhaus sind vor allem in den USA häufig, wo die Liegezeiten aus Kostengründen niedrig gehalten werden. Die Folge ist, dass etwa 20% der Patienten in den folgenden 30 Tagen erneut in der Klinik behandelt werden müssen, häufig mit vermeidbaren Komplikationen. Ein Team vom Inselspital in Bern hat nach einer Möglichkeit gesucht, Patienten mit drohender Wiederaufnahme bereits bei der Entlassung zu erkennen. Das Ergebnis war der HOSPITAL-Score, der anhand von sieben Laborwerten oder Patienteneigenschaften eine Vorhersage ermöglichen soll. Diese Prädiktoren sind: tiefer Hämoglobin-Spiegel (H), Entlassung aus der Onkologie (O), Hyponatriämie (S für Sodium), Intervention (P für Procedure), Notfalleintritt (IT für Index Type urgent), Anzahl der Hospitalisierungen (A für Admissions) im letzten Jahr sowie ein Aufenthalt von 5 Tagen oder mehr (L für Length). Das Ergebnis ist ein Score, der einen Wert von 0 bis 13 Punkten annehmen kann.

Der Score wurde jetzt an den Daten von 117.065 Patienten validiert, die an 6 Kliniken in den USA sowie jeweils einer Klinik in Kanada, Israel und der Schweiz behandelt worden waren: Insgesamt 16.992 Patienten (14,5%) wurden innerhalb von 30 Tagen erneut aufgenommen, bei 11.307 Patienten (9,7%) wurde dies als vermeidbar eingestuft. Wie die Wissenschaftler berichten, wurde das Risiko einer Wiederaufnahme für Patienten mit einem Score von 0 bis 4 Punkten als gering eingestuft. Hier kam es bei 5,8% zu einer vermeidbaren Wiederaufnahme. Bei 27.612 Patienten (24%) gingen die Autoren aufgrund eines HOSPITAL-Scores von 5 bis 6 Punkten von einem intermediärem Risiko aus. Die Rate der vermeidbaren Wiederaufnahmen betrug in dieser Gruppe 11,9%. Bei den 16.244 Patienten (14%) mit einem Score von 7 bis 13 Punkten und damit einem hohen Risiko kam es zu 22,8% zu einer Wiederaufnahme, also viermal häufiger als bei Patienten mit einem niedrigen Score. Der Score erzielte in der C-Statistik einen Wert von 0,72 (1 wäre eine sichere Vorhersage), der sich laut den Autoren durchaus mit anderen Scores messen lassen kann. Die zur Vorhersage des Schlaganfalls verwendeten CHADS2- und CHADS2-VASC-Scores erzielten einen Wert von 0,68.

Quelle: Deutsches Ärzteblatt www.aerzteblatt.de basierend auf: Donzé JD, Williams MV, Robinson EJ (2016) International Validity of the HOSPITAL Score to Predict 30-Day Potentially Avoidable Hospital Readmissions. JAMA Intern Med 176(4):496–502